

Molecular Diagnostics Partnering Terms and Agreements

Published: October 2014

Single User PDF: US\$ 1995

Corporate User PDF: US\$ 9995

















The <u>Molecular Diagnostics Partnering Terms and Agreements</u> report provides a detailed understanding and analysis of how and why companies enter molecular diagnostics partnering deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. This report provides details of the latest molecular diagnostics agreements announced in the healthcare sectors.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of all molecular diagnostics partnering deals announced since 2009 including financial terms where available including over 300 links to online deal records of actual molecular diagnostics partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

Single User License Available US \$1995 Order a copy of this report at @ http://www.reportsnreports.com/Purchase.aspx?name=300707.



Molecular Diagnostics Partnering Terms and Agreements



The initial chapters of this report provide an orientation of drug dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in molecular diagnostics dealmaking since 2009, including details of average headline, upfront, milestone and royalty terms. Chapter 3 provides a review of the leading molecular diagnostics deals since 2009. Deals are listed by headline value, signed by big pharma, big biotech, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract. Chapter 4 provides a comprehensive listing of the top 50 big pharma companies with a brief summary followed by a comprehensive listing of molecular diagnostics deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand. Chapter 5 provides a comprehensive listing of the top 50 big biotech companies with a brief summary followed by a comprehensive listing of molecular diagnostics deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand. Chapter 6 provides a comprehensive and detailed review of molecular diagnostics partnering deals signed and announced since 2009, where a contract document is available in the public domain.

Inquire for this report @

http://www.reportsnreports.com/contacts/InquiryBeforeBuy.aspx?name=300707

Molecular Diagnostics Partnering Terms and Agreements





Report scope

Molecular Diagnostics Partnering Agreements is intended to provide the reader with an in-depth understanding and access to molecular diagnostics trends and structure of deals entered into by leading companies worldwide.

Molecular Diagnostics Partnering Agreements includes:

Trends in molecular diagnostics dealmaking in the biopharma industry since 2009

Analysis of molecular diagnostics deal structure

Access to headline, upfront, milestone and royalty data

Access to over 300 molecular diagnostics deal records

The leading molecular diagnostics deals by value since 2009

In Molecular Diagnostics Partnering Agreements, the available deals are listed by:

Company A-Z

Headline value

Stage of development at signing

Deal component type

Specific diagnostics technology type







Molecular Diagnostics Partnering Terms and Agreements provides the reader with the following key benefits:

In-depth understanding of molecular diagnostics deal trends since 2009

Access molecular diagnostics deal headline, upfront, milestone and royalty data

Analysis of the structure of molecular diagnostics agreements with numerous real life case studies

Comprehensive access to over 300 links to actual infectious vaccines deals entered into by the world's biopharma companies, together with real world clause examples

Identify leading molecular diagnostics deals by value since 2009

Identify the most active molecular diagnostics dealmakers since 2009

Insight into the terms included in molecular diagnostics agreement, together with real world clause examples

Understand the key deal terms companies have agreed in previous deals

Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Inquire for Discount @ http://www.reportsnreports.com/contacts/Discount.aspx?name=300707.

Browse more report on **Pharmaceuticals Market**